

LA-UR-15-27220 (Accepted Manuscript)

Permeability barrier of Gram-negative cell envelopes and approaches to bypass it

Zgurskay, Helen I
Lopez Bautista, Cesar Augusto
Gnanakaran, Sandrasegaram

Provided by the author(s) and the Los Alamos National Laboratory (0000-00-00).

To be published in: ACS Infectious Diseases, 2015, 1 (11), pp 512–522

DOI to publisher's version: 10.1021/acsinfecdis.5b00097

Permalink to record: <http://permalink.lanl.gov/object/view?what=info:lanl-repo/lareport/LA-UR-15-27220>

Disclaimer:

Approved for public release. Los Alamos National Laboratory, an affirmative action/equal opportunity employer, is operated by the Los Alamos National Security, LLC for the National Nuclear Security Administration of the U.S. Department of Energy under contract DE-AC52-06NA25396. Los Alamos National Laboratory strongly supports academic freedom and a researcher's right to publish; as an institution, however, the Laboratory does not endorse the viewpoint of a publication or guarantee its technical correctness.

The permeability barrier of Gram-negative cell envelopes and approaches to bypass it

Helen I. Zgurskaya¹, Cesar A. López², Sandrasegaram Gnanakaran²

¹ University of Oklahoma, Department of Chemistry and Biochemistry, 101 Stephenson Parkway, Norman, OK 73019; Phone: 405-325-1678; Fax: 405-325-6111; email: elenaz@ou.edu

² Los Alamos National Laboratory, Los Alamos, NM 87545

Keywords: **gram-negative resistance, permeability barrier, outer membrane, multi-drug efflux**

Abstract

Gram-negative bacteria are intrinsically resistant to many antibiotics. Species that acquired multi-drug resistance and cause infections that are effectively untreatable present a serious threat to public health. The problem is broadly recognized and tackled at both the fundamental and applied levels. This article summarizes current advances in understanding the molecular bases of the low permeability barrier of Gram-negative pathogens, which is the major obstacle in discovery and development of antibiotics effective against such pathogens. Gaps in knowledge and specific strategies to break this barrier and to achieve potent activities against difficult Gram-negative bacteria are also discussed.

Gram-negative pathogens and challenges of antibiotic discovery

Drug resistance presents an ever-increasing threat to public health and encompasses all major microbial pathogens and antimicrobial drugs ^{1, 2}. Some pathogens have acquired resistance to multiple antibiotics and cause infections that are effectively untreatable. Among pathogenic Gram-negative *Enterobacteriaceae*, *Acinetobacter* and *Pseudomonas*, species have emerged that are resistant to all good antibiotics ³. One of the most troubling event is the worldwide spread of carbapenem-resistant *Klebsiella* spp.⁴. Infections caused by these resistant variants have the mortality rate of up to 50%. By 2013, 17% of *Escherichia coli* infections became multi-drug resistant. In some regions, fluoroquinolones are no longer on the lists of recommended treatment options^{5, 6}. Such environmental species as *P. aeruginosa*, *Stenotrophomonas maltophilia*, *Burkholderia cepacia* complex (Bcc) and *A. baumannii* are intrinsically resistant to antibiotics. Among these species, *P. aeruginosa* is a common nosocomial pathogen, the causative agent of many life-threatening infections and the major reason for the shortened life span of people with cystic fibrosis. *P. aeruginosa* infections can be successfully treated by only a few specific representatives of fluoroquinolones, β -lactams, or aminoglycosides. However, even these few antibiotics fail against antibiotic resistant *P. aeruginosa* isolates. Thus, there is a strong need for new therapeutic options, particularly those directed against multi-resistant Gram-negative bacteria.

The discovery of new antibiotics effective against Gram-negative bacteria is a major challenge, primarily because of the low hit rate during screening of compound libraries, which is up to 1000 fold lower in *P. aeruginosa* than against Gram-positive bacteria ⁷. The major reasons for such low hit rate are the low permeability barrier of two-membrane cell envelopes of Gram-negative bacteria and insufficient chemical diversity of compound libraries to probe this barrier. Gram-negative bacteria vary significantly in their permeability to antibiotics, but one could expect that the basic principles established by extensive studies of *E. coli* would apply equally to such “impermeable” species as *Burkholderia* spp or *Pseudomonas* spp. It remains unclear however, whether permeation rules⁸, in analogy with Lipinski’s rules⁹, if such existed and applied to structure-activity relationships or to filtering compound libraries, would yield compounds that permeate all Gram-negative barriers. Here, we briefly review the current state of understanding of the molecular bases of low permeability barriers of problematic Gram-negative pathogens and the current efforts to define physico-chemical properties that enable uptake of various compounds into bacterial cells.

The two-membrane barrier of Gram-negative bacteria

Susceptibility of Gram-negative bacteria to antibiotics is defined by two opposing fluxes across the two membranes of these species (Fig. 1) ¹⁰⁻¹². The influx and uptake of antibiotics are significantly slowed down by the elaborate outer membrane (OM). This membrane is an asymmetric bilayer of lipopolysaccharides (LPS) and phospholipids, into which non-specific porins and specific uptake channels are embedded ^{13, 14}. The LPS-containing bilayers are more rigid than normal bilayers, slowing passive diffusion of hydrophobic compounds, whereas narrow pores limit by size the penetration of hydrophilic drugs. The slow influx of drugs across the OM is further opposed by active efflux mediated by multidrug efflux transporters. Multidrug efflux transporters are structurally and functionally diverse with some transporters pumping antibiotics across the inner membrane and reducing concentrations of antibiotics in the cytoplasm, whereas others expelling antibiotics from the periplasm into the external medium. The later transporters confer resistance to antibiotics by associating with the periplasmic and OM accessory proteins to form trans-envelope complexes ^{15, 16}. These complexes enable conversion of the energy stored in the inner membrane into active efflux of antibiotics across the OM. Efflux of antibiotics across the inner membrane acts synergistically with the trans-envelope efflux and, as a result, inactivation of efflux pumps leads to dramatic sensitization of Gram-negative bacteria to antibiotics. The clinical relevance of the multi-drug efflux of antibiotics has also been established. For example, in clinical isolates of *E. coli* and *K. pneumonia*, fluoroquinolone resistance is linked to overproduction of AcrAB-TolC efflux pump, whereas multiple efflux pumps confer antibiotic resistance in *P. aeruginosa*, *Burkholderia* spp. and *A. baumannii* ¹⁷⁻²⁰. The interplay between uptake and efflux define the steady-state accumulation level of antibiotics at targets.

Composition and properties of LPS-containing bilayers.

Despite similar organization, the outer membranes of Gram-negative bacteria differ dramatically in their permeability properties. These differences are largely attributed to differences in composition and permeability properties of general porins^{12, 14} (see also below), but the chemical structure and properties of LPS-containing bilayer could also play an important role. Typical LPS comprises a basic lipid A structure containing an *N*- and *O*-acylated diglucosamine bisphosphate backbone. Chemical variations of lipid A among species involve the number of primary acyl groups and the types of fatty acids substituting the primary and secondary acyl groups (Fig. 2). *Escherichia* lipid A is most frequently described as a hexaacylated molecular

species although penta-, and tetra-acylated molecules are also present in varying amounts²¹. Most of the laboratory-adapted strains of *P. aeruginosa* synthesize a penta-acylated (75% of the molecules) LPS, with some proportion made as a hexa-acylated LPS (25% of the molecules)^{22, 23}. Growth conditions, notably magnesium levels, can affect the acylation pattern of *P. aeruginosa* lipid A. Among isolates from chronically infected CF patients, which are known to be mutants generally unable to synthesize O-antigen side chains, a hexa-acylated LPS form predominates, although a hepta-acylated lipid A has been isolated, containing an additional palmitoyl (C16:0) group linked to the primary 3-hydroxy decanoic acid group at position 3' of glucosamine 2^{24, 25}. The hexa- and hepta-acylated lipid A moieties also contain cationic 4-amino-4-deoxy-L-arabinose sugars. Similarly, the major lipid A species in *Burkholderia* spp. (*B. cepacia*, *B. mallei*, *B. pseudomallei*) consists of a biphosphorylated disaccharide backbone, which is constitutively modified with 4-amino-4-deoxy-L-arabinose and penta- or tetra-acylated²⁶. Lipid A of *A. baumannii* is often modified by phosphorylethanolamine and an unusual sugar galactosamine and hexa- and hepta-acylated²⁷ (Fig. 2).

Early studies showed that the permeability of *E. coli* and *P. aeruginosa* OM to hydrophobic steroid probes is similar, suggesting that the differences in the lipid A acylation state and the length of fatty acids do not affect significantly the OM permeability to small planar molecules^{28, 29}. On the other hand, amphiphilic and charged molecules are likely to interact with the backbone of lipid A and LPS cores and their permeation could be sensitive to modifications of both the lipids and polysaccharides of the LPS-containing bilayers.

LPS cores of enterobacteria typically consist of 8–12 often branched sugar units³⁰. The sugar at the reducing end is always α -3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) (2→6)-linked to lipid A. At the C-4 position of Kdo, there may be one or two Kdo groupings. Three L-glycero-D-manno-heptose residues are also (1→5)-linked to the first Kdo. A heptose residue may be substituted by a phosphate, pyrophosphate, or phosphorylethanolamine group, or by another sugar to make up the inner core. In *Pseudomonas* spp. cores, one often finds an alanyl group substituting a GalN residue, and a carbamoyl group on heptose I³¹. *P. aeruginosa* PAO1 serotype O5 and its two rough-type mutants share these characteristics, but have in addition three phosphomonoester groups on their heptose^{31, 32}. It was suggested that these groups play a role in interactions with antibiotics. Some *Acinetobacter* and *Burkholderia* spp. produce LPS cores devoid of heptose. *B. cepacia* and *A. haemolyticus* synthesize and incorporate the Kdo analogue D-glycero-D-talo-oct-2-ulosonic acid (Ko)³³⁻³⁵

The O-chains determine the specificity of each bacterial serotype. A combination of monosaccharide diversity, the numerous possibilities of glycosidic linkage, substitution and configuration of sugars, and the genetic capacities of the diverse organisms, have all contributed to the uniqueness of the great majority of O-chain structures.

It is broadly accepted that LPS cores and lipid A of enterobacteria and *P. aeruginosa* are modified in response to specific growth conditions and stresses (Fig. 2)³⁶⁻³⁸. These modifications are critical under the low magnesium ion conditions that destabilize the LPS leaflet and increase permeability of the OM, as well as in the development of resistance to cationic peptides including polymixins^{36, 39}. However, in *Acinetobacter spp.* and *Burkholderia spp.* some of the modifications are constitutive (Fig. 2). How the phosphate, pyrophosphate, or phosphorylethanolamine groups on Kdo and heptoses, terminal sugars, amino acid and other groups occurring non-stoichiometrically correlate with specific growth conditions of these bacteria remains unclear. Even less is known how these modifications affect the packing and rigidity of the LPS layer and its interactions with proteins and small molecules in the context of the outer membrane.

The recent advances in molecular dynamics (MD) simulations of asymmetric bilayers containing LPS offer first glimpses into packing and dynamics of such structures^{40, 41}. The inner leaflet of the outer membrane is composed of phospholipids and with the composition similar to that of the cytoplasmic membrane. Hence, the geometry of the LPS leaflet should match that of the phospholipid leaflet. Based on MD simulations LPS-containing bilayers appear to be more disordered and thinner than bilayers assembled from phospholipids only. Magnesium ions form a layer of ionic bonds with phosphoryl moieties of lipid A and the core and stabilize LPS molecules in the bilayers. Packing and rigidity of LPS bilayers are expected to affect permeation of amphiphilic and hydrophobic antibiotics. However, this picture remains incomplete because about 50% of the *E. coli* OM mass consists of protein and the OM resembles a LPS-protein aggregate.

Outer membrane proteins and permeability.

In *E. coli*, a few integral membrane proteins, such as OmpA and the general porins OmpF/C, are expressed at high levels (Table 1). Besides these, there are minor proteins whose synthesis in some cases is strongly induced when they are needed, such as specific porins (e.g. PhoE and LamB), TonB-dependent receptors (e.g. FhuA and FepA), components of several protein export systems, proteins involved in the biogenesis of flagella and pili, and enzymes (e.g. OmpT protease and phospholipase A^{14, 42}). The permeability properties of *E. coli* membranes are

largely defined by general porins that have an exclusion limit at about 600 Da for OmpF. Most hydrophilic and amphiphilic antibiotics reach the periplasm through porins, whereas larger antibiotics, for example erythromycin or novobiocin are believed to cross the outer membrane through lipid bilayer by diffusion, which is expected to be slow^{14, 43}.

The existing paradigm that only small molecules (MW ~600 Da) can cross the membrane by passive diffusion has recently been challenged by studies of CymA channel from *Klebsiella oxytoca*⁴⁴. CymA mediates diffusion of cyclodextrins with the diameter up to 15 Å by a novel mechanism, which involves a mobile N-terminal peptide acting as a periplasmic gate. Binding of the incoming substrate displaces the N-terminal constriction and allows diffusion of the bulky molecule without compromising the permeability barrier of the OM. One could imagine that antibiotics could be modified in a way to mimic the interactions of substrates with specific porins and facilitate their own diffusion across the OM.

In addition, some leakage of large antibiotics is possible through export systems. *E. coli* cells lacking TolC channel, which is involved in efflux of antibiotics and export of proteins as a part of the type I secretion pathway, are less susceptible to vancomycin than the wild type cells suggesting some penetration of this ~1200 Da molecule through TolC^{45, 46}. Interestingly, this penetration requires the presence of active AcrAB transporter further suggesting that vancomycin slips through TolC when it is engaged by AcrAB pump (see also below). It is possible that permeation through other specific porins and TonB-dependent channels, the Bam complex responsible for the assembly of the outer membrane and at protein-LPS interfaces also contribute to the intracellular accumulation of antibiotics.

The overall compositions and architectures of *Pseudomonas spp.* and *Acinetobacter spp.* outer membranes are similar to other Gram-negative bacteria⁴⁷. About 160 various proteins are embedded into the asymmetric bilayer and play a role in generalized and specific uptake and export of various compounds and polypeptides. Unlike enterobacteria, outer membranes of Pseudomonads and *Acinetobacter spp.* do not contain general trimeric porins such as OmpF and OmpC of *E. coli*. It is estimated that the permeability of *P. aeruginosa* and *A. baumannii* outer membranes is only 1-8% of that *E. coli* and that non-specific “slow” porins OprF and OprA, respectively, restrict access of molecules larger than ~200 Da, which is the size of a typical monosaccharide⁴⁷⁻⁴⁹. However, the growth rate of *P. aeruginosa* as well as of *A. baumannii* in a rich medium is comparable to that of *E. coli* and hence to sustain the high rate of metabolism, the net influx of nutrients is expected to be comparable for the three species. *P. aeruginosa* likely solves this conundrum of the low permeability of the outer membrane despite

the high nutrient uptake in several ways: (i) by secreting degrading enzymes that convert larger molecules into mono-units (pseudomonads are masters of biodegradation); (ii) by producing a larger fraction of substrate-specific channels (such as OprB and OprD); and (iii) by transiently producing large porins (i.e. an open conformer of OprF).

OprF is one of the most abundant protein in *P. aeruginosa* with a copy number of 200,000 per cell⁴⁷. This protein plays a structural role by associating with LPS and peptidoglycan. *P. aeruginosa* mutants deficient in OprF synthesis have an almost spherical appearance, are shorter than wild-type cells and do not grow in low osmolarity medium. OprF also plays an important non-specific uptake function by existing in closed and open conformations (400 open conformers out of 200,000 total OprF)^{50, 51}. Even a low copy number of open OprF could make a significant difference in net influx of small and large molecules. The open OprF is also likely to be a route for some of the hydrophilic antibiotics to get access to the periplasm. Much less is known about the major porin OmpA of *A. baumannii*. This protein has a permeability similar to that OprF and also plays both the structural and uptake roles in the outer membrane but whether or not it exists as different conformers is unclear⁵².

In addition to “slow” porins, *P. aeruginosa* and *A. baumannii* use specific porins for uptake of small molecules. The large number of specific porins provides an advantage in nutrient deficient environments, but could be limiting in rich growth media. *P. aeruginosa* OprB, specific for glucose uptake and OprD, specific for the diffusion of basic amino acids and peptides, are best characterized. OprD is the primary channel for the entry of carbapenems across the OM, and the reduced expression or loss of OprD has been frequently observed in carbapenem-resistant clinical isolates. *A. baumannii* produces an OprD homolog CarO, but whether or not this porin provides a path for carbenems remains under debate^{53, 54}.

Interestingly, although the outer membrane permeability of *A. baumannii* to cephalothin and cephaloridine, measured in intact cells, was found to be about 100-fold lower than that of *E. coli* K-12⁵², these cells are more susceptible to such large antibiotics such as novobiocin and erythromycin^{28, 55}. Many *Acinetobacter* spp. are capable of using long-chain hydrocarbons as growth substrates suggesting that their LPS-phospholipid bilayers of the outer membrane are more permeable for the hydrophobic molecules⁵⁵.

Outer membranes of *Burkholderia* spp. contain a trimeric general porin Omp38 (OpcP), a homolog of *E. coli* OmpF⁵⁶⁻⁵⁸. The two studies of Omp38 permeability produced contradictory results: this porin is either similar to *E. coli* OmpF or by 1 or 2 orders of magnitude is less permeable than OmpF. Further studies are needed to analyze the properties of porins and outer

membranes for challenging Gram-negative bacteria such as *A. baumannii* and *Burkholderia spp.*

Efflux pumps

Efflux across the outer membrane. All Gram-negative bacteria examined so far contain at least one multidrug efflux transporter responsible for protection against a variety of antimicrobial agents^{10, 11}. AcrAB-TolC of *E. coli*, is the best characterized efflux pump and its homologs are broadly represented in enterobacteria and other Gram-negative species^{16, 59-61}. In this three-component complex, AcrB is a proton-motive force driven transporter from Resistance-Nodulation-Division (RND) superfamily of proteins, TolC is an outer membrane channel and AcrA is a periplasmic Membrane Fusion Protein (MFP). The three proteins form a trans-envelope complex that expels multiple antibiotics from *E. coli* cells^{62, 63}. Extensive structural and functional analyses, including our own studies, showed that AcrB captures its substrates from the membrane and from the periplasm and expels them through TolC channel into external medium with the help of AcrA protein⁶⁴⁻⁶⁶. At least two substrate binding sites in AcrB, the proximal and the distal, are both located in the periplasmic domains of the protein. Thus, unlike other typical secondary transporters, AcrB with the help of AcrA and TolC expels substrates across the outer membrane, while driven by the proton transfer across the cytoplasmic membrane. All RND-type multidrug efflux pumps are likely to share this mechanism but it remains unclear whether some of these protein complexes can actually pump substrates not only across the outer but also across the inner membrane, thus performing the trans-envelope efflux of antibiotics from the cytoplasm directly into the external medium.

Among AcrAB-TolC substrates are organic solvents, antibiotics, detergents, dyes and even hormones. Examination of chemical structures, as well as cocrystallization and molecular dynamics studies significantly advanced understanding of the molecular mechanism of multidrug recognition by AcrB^{67, 68}. However, physicochemical properties of compounds that would distinguish AcrB substrates from non-substrates remain elusive. The current consensus is that AcrAB-TolC is the most effective against amphiphilic compounds that diffuse slowly across the OM. Recent attempts to determine the affinity of AcrAB-TolC toward its substrates demonstrated convincingly that minimal inhibitory concentrations of antibiotics is a very poor, if at all, measure of whether an antibiotic is a good or a bad substrate of an efflux pump⁶⁹. Several uptake assays were developed to analyze drug efflux with most of them informative in both *E. coli* and *P. aeruginosa*. However, further characterization of kinetic behavior of efflux pumps in the context of two-membrane envelopes of Gram-negative bacteria is needed.

P. aeruginosa MexAB-OprM is a close homolog of AcrAB-TolC and the major “house-keeping” efflux pump but it is not the only pump, which is expressed and contributes to antibiotic resistance in this species. The constitutive expression of MexAB-OprM confers intrinsic antibiotic resistance¹⁷⁻¹⁹, whereas elevated expression of MexXY-OprM is the major cause of aminoglycoside resistance in the absence of modifying enzymes⁷⁰. In addition, efflux pumps MexCD-OprJ and MexEF-OprN are often overproduced in multiresistant clinical isolates. MexEF-OprN and MexGHI-OprD play important roles in *P. aeruginosa* physiology and are involved in secretion of quorum sensing signals and biofilm formation⁷¹⁻⁷³. Furthermore, *P. aeruginosa* lacking either MexAB or MexHI is attenuated in animal models^{73, 74}.

As in the case of *P. aeruginosa*, genomes of *Burkholderia spp.* and *Acinetobacter spp.* contain multiple operons encoding RND-type efflux pumps. Some of these pumps are constitutively expressed and confer intrinsic antibiotic resistance, whereas other are inducible and expressed under specific physiological conditions. AmrAB-OprA *B. pseudomallei* and its homologs in other *Burkholderia spp.* are largely responsible for intrinsic antibiotic resistance⁷⁵. AmrAB-OprA is closely related to MexXY-OprM of *P. aeruginosa* and in addition to various antibiotics, confers resistance to aminoglycosides. In the most comprehensive genetic analysis, deletion of the 16 putative RND operons from *B. cenocepacia* strain J2315 showed that these pumps play differential roles in the drug resistance of sessile (biofilm) and planktonic cells. These studies revealed that: (1) RND-3 (a homolog of AmrAB-OprA) and RND-4 play important roles in resistance to various antibiotics, including fluoroquinolones and aminoglycosides, in planktonic populations; (2) RND-3, RND-8, and RND-9 protect from the antimicrobial effects of tobramycin in biofilm cells; and (3) RND-8 and RND-9 do not play a role in ciprofloxacin resistance⁷⁶.

A. baumannii genome encodes seven RND-type efflux pumps. AdeIJK confers intrinsic resistance to various antibiotics including beta-lactams, fluoroquinolones, tetracyclines, lincosamides and chloramphenicol. In addition, AdeABC and AdeFGH are overproduced in clinical multidrug resistant isolates⁷⁷. Surprisingly, overproduction of AdeABC and AdeIJK could also alter bacterial membrane composition, resulting in decreased biofilm formation but not motility⁷⁸. When expressed in *E. coli* at the levels comparable to those of AcrAB-TolC, AdeIJK but not AdeABC was more effective in removal of lipophilic β-lactams, novobiocin, and ethidium bromide⁷⁸.

Efflux across the cytoplasmic membrane. Highly abundant in genomes of various Gram-negative bacteria, single component transporters extruding drugs from the cytoplasm into

periplasm remain understudied in clinical settings, in part because their drug efflux activities are important only in the context of intact OM and in the presence of active efflux across the OM. Inactivation of single component transporters that pump antibiotics across the inner membrane usually does not lead to significant changes in susceptibilities to antibiotics⁷⁹. However, inactivation of multiple such pumps in *E. coli* is able to negate even the activity of AcrAB-TolC⁸⁰.

Drug-specific transporters, such as TetA and similar, are also spread by plasmids and their contribution could be either additive or multiplicative depending on the combination of transporters expressed in host cells⁸¹. Experimental data and kinetic modeling showed that the co-expression of single- and three-component transporters leads to a synergistic loss of susceptibility to shared substrates^{81, 82}.

Single component transporters can belong to one of the three protein families: Small Multidrug Resistance (SMR), Major Facilitator Superfamily (MFS) or Multidrug and Toxic Extrusion (MATE).

E. coli SMR transporter EmrE, MFS MdfA and MATE transporter NorE are the best characterized representatives⁸³⁻⁸⁵. MdfA and NorE are commonly expressed in fluoroquinolone-resistant isolates and contribute to resistance against these antibiotics⁷⁸. Properties and mechanisms of these proteins are well-characterized but very little is known about their homologs in “difficult” Gram-negative pathogens.

Approaches to bypass or break the permeability barrier

In general, several approaches are envisioned how antibiotic penetration across the permeability barrier of Gram-negative bacteria could be improved but all these approaches suffer from intrinsic limitations that need to be further addressed for new therapeutics to emerge.

Inhibition of new accessible targets

The most traditional approach would be to identify new accessible targets on cell surfaces or in the periplasm that could be interrogated in drug discovery efforts. The major bottleneck here is that such targets are optimized over millions years of evolution to be resistant to antibiotics. On the other hand, recent breakthroughs in understanding the molecular mechanisms of cell envelope assembly promise that such goal is attainable, albeit through the more target oriented approach. LPS biosynthesis pathway has been considered a highly attractive target in Gram-

negative bacteria for decades^{7, 86}. There are two drug candidates in clinical trials that target this pathway in *P. aeruginosa*⁸⁷. ACHN-975 (Achaogen) is a synthetic molecule that inhibits LpxC deacylase and POL7080 (Polyphor) is a synthetic peptide targeting the outer membrane protein LptD, involved in exporting LPS molecules across the periplasm. In addition to targeting essential enzymes, these inhibitors are expected to be synergistic with other antibiotics by enabling their permeation across the cell envelope.

Identification of uptake pathways and the “Trojan Horse” approach.

Another approach to bypass the permeability problem would be to achieve fast or facilitated uptake of an antibiotic. Such efficient uptake would negate the impact of efflux and increase the concentration of an antibiotic at the target. As discussed above, *Pae* and other “impermeable” Gram-negative species rely on specific porins and active uptake system to fulfil their metabolic demands and to maximize their growth rates. These pathways could be potentially exploited for delivery of antibiotics to their targets through the characterization of specificity determinants and modification of antibiotics to enable their uptake through such specific systems. The major limitation of such approach is a high frequency of resistance because the pathways are redundant and non-essential. However, identification and exploitation of uptake systems that are essential during establishment and proliferation of infections could facilitate the development of new therapeutics.

The “Trojan Horse” approach, which is largely derived from siderophore- conjugated antibiotics, is an example of such a strategy. Siderophore-conjugated antibiotics can be actively transported into the periplasm and cytoplasm by various iron-uptake systems⁸⁸. A common pathway of bacterial siderophore transport systems in Gram-negative bacteria has been identified⁸⁹. An outer membrane transporter binds the Fe³⁺-siderophore complex with an affinity in the range of 1 nM and translocates this complex across the outer membrane with the help of TonB protein anchored in the cytoplasmic membrane. This process is driven by the cytoplasmic membrane potential. The Fe³⁺-siderophore in the periplasm is bound by a binding protein that delivers its cargo via the cognate ABC transporter into the cytoplasm. Alternatively, the reduced iron is unloaded in the periplasm, as in the case of yersiniabactin and *P. aeruginosa* pyoverdines⁹⁰. Hence, siderophore-conjugated antibiotics could be delivered by such uptake pathways either into periplasm or all the way into cytoplasm⁹¹. BAL30072 (Basilea) is the only candidate currently in clinical trials⁹². This compound is a monocyclic β -lactam conjugated to a dihydropyridone siderophore moiety, which has a potent activity against multi-drug resistant Gram-negative pathogens including “impermeable” species.

Studies of natural peptide antibiotics suggested additional pathways that could be exploited for bypassing the “impermeable” cell envelopes. Pacidamycins are uridyl peptide antibiotics, which specifically kill strains against *P. aeruginosa*⁹³⁻⁹⁵. These antibiotics inhibit MraY translocase catalyzing the first step in peptidoglycan synthesis. With the MW >800 Da, pacidamycins cannot penetrate the OM but exploit a specific uptake system to reach the target. The ABC transporter NppABCD belonging to PepT family of transporters is implicated in the uptake of pacidamycin and other peptidyl nucleoside antibiotics such as blastidin S, albomycin and microcin C, across the inner membrane⁹⁶. These antibiotics are likely to cross the OM through the TonB-dependent receptors involved in uptake of siderophores.

Rules of permeation.

It is likely that the permeation of different classes of compounds is affected by the outer membrane barrier and by the active efflux to different degrees. At present no rules exist to predict whether increasing uptake or reducing efflux would be the most efficient way to increase the potency of a specific class of compounds. It is believed that these rules will emerge when we address a critical gap in knowledge about what physicochemical properties and specific functional groups define the permeation of compounds across cell walls of Gram-negative pathogens⁸. Having such rules to guide medicinal chemistry efforts could potentially facilitate the discovery of novel anti-Gram negative drugs⁹⁷. Although the task is complex, the recent success with development of a predictive model for drug accumulation in *Caenorhabditis elegans*⁹⁸ is inspiring. Several investigators including this author lead the efforts to develop experimental approaches and to generate representative data sets of compound penetration into difficult Gram-negative pathogens^{99, 100}. These studies complement the activity-based approaches to identify physico-chemical properties that facilitate efflux of compounds¹⁰¹.

In addition, first bacterial membrane models reflecting the biological complexity are emerging and could be used to address a wide range of questions about protein-lipid packing and dynamics that are not accessible by experiments¹⁰². With these models and methods it is now possible to study interactions of antimicrobial peptides and antibiotics with membranes and to identify their preferable penetration routes¹⁰³.

Efflux pump inhibitors.

The unquestionably significant impact of multidrug efflux pumps on bacterial physiology and the resistance to antibiotics in clinical settings makes them attractive targets for inhibition. Several classes of efflux pump inhibitors (EPIs) have been reported in the literature and are being pursued in drug development programs¹⁰⁴⁻¹⁰⁸. Phenylalanyl-arginyl-β-naphthylamide and

analogous arylamines are broad-spectrum EPIs with activities against Gram-negative bacteria^{105, 109, 110}, arylpiperidines¹¹¹ and more recently pyrinopyridine¹¹² are inhibitors of AcrAB-TolC from *E. coli*. Likewise, pyridopyrimidines are specific inhibitors of MexAB-OprM from *P. aeruginosa* and quinazoline derivatives are able to potentiate multiple antibiotics against both Enterobacteriaceae and *P. aeruginosa*¹¹³. Importantly, broad-spectrum EPIs that target multiple efflux pumps have been reported not only to restore activities of antibiotics but also to reduce frequencies of antibiotic resistance¹¹⁴. As with many combination therapies, the task of EPIs development is not easy and must overcome multiple hurdles starting with choice of the antibiotic for potentiation and all the way to matching the pharmacological properties of an EPI/antibiotic pair¹⁰⁷. At the same time, some efflux pumps are critical for virulence and biofilm formation, i.a. MexGHI-OpmH and MexEF-OprN from *P. aeruginosa*. EPIs effective against such transporters, if available, could be useful alternative therapeutics on their own.

Conclusions

The emerging multi-drug resistant Gram-negative pathogens present a significant challenge in clinics that should be addressed in a timely manner. Several decades of antibiotic discovery experience suggested that the permeability barrier is the major hurdle in the development of new therapeutics against these pathogens. Significant efforts are currently directed at understanding at the molecular level both the permeability properties of the OM from different bacterial species, as well as at finding correlations between physico-chemical properties of compounds and their permeation across the two membrane cell envelopes in the presence of efflux. The task is complex and multi-faceted but could be achieved by combined efforts at the government, industry and academy levels.

Acknowledgement

Studies in Zgurskaya lab are sponsored by the Department of the Defense, Defense Threat Reduction Agency and by the National Institute of Health (grant AI052293). The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred.

References

[1] Levy, S. B., and Marshall, B. (2004) Antibacterial resistance worldwide: causes, challenges and responses, *Nat Med.*

[2] Sievert, D. M. P., Ricks, P. P., Edwards, J. R. M. S., Schneider, A. M. P. H., Patel, J. P., Srinivasan, A. M. D., Kallen, A. M. D., Limbago, B. P., Fridkin, S. M. D., for the National Healthcare Safety Network, T., and Participating, N. F. (2013) Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010, *Infection Control and Hospital Epidemiology* 34, 1-14.

[3] Livermore, D. M. (2004) The need for new antibiotics, *Clin Microbiol Infect* 10 Suppl 4, 1-9.

[4] Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., Kumarasamy, K., Livermore, D. M., Maya, J. J., Nordmann, P., Patel, J. B., Paterson, D. L., Pitout, J., Villegas, M. V., Wang, H., Woodford, N., and Quinn, J. P. (2013) Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases, *The Lancet Infectious Diseases* 13, 785-796.

[5] Rice, L. B. (2012) Mechanisms of Resistance and Clinical Relevance of Resistance to β -Lactams, Glycopeptides, and Fluoroquinolones, *Mayo Clinic Proceedings* 87, 198-208.

[6] Vasoo, S., Barreto, J. N., and Tosh, P. K. (2015) Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician, *Mayo Clinic Proceedings* 90, 395-403.

[7] Silver, L. L. (2011) Challenges of Antibacterial Discovery, *Clinical Microbiology Reviews* 24, 71-109.

[8] Lewis, K. (2012) Antibiotics: Recover the lost art of drug discovery, *Nature* 485, 439-440.

[9] Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv Drug Deliv Rev* 46, 3-26.

[10] Zgurskaya, H. I. (2009) Mechanisms of drug efflux and strategies to combat them. Preface, *Biochim Biophys Acta* 1794, 723-724.

[11] Nikaido, H. (2009) Multidrug Resistance in Bacteria, *Annu Rev Biochem.*

[12] Li, X.-Z., Plésiat, P., and Nikaido, H. (2015) The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria, *Clinical Microbiology Reviews* 28, 337-418.

[13] Delcour, A. H. (2009) Outer membrane permeability and antibiotic resistance, *Biochim Biophys Acta* 1794, 808-816.

[14] Nikaido, H. (2003) Molecular basis of bacterial outer membrane permeability revisited, *Microbiology and molecular biology reviews : MMBR* 67, 593-656.

[15] Lomovskaya, O., Zgurskaya, H. I., Totrov, M., and Watkins, W. J. (2007) Waltzing transporters and 'the dance macabre' between humans and bacteria, *Nature reviews. Drug discovery* 6, 56-65.

[16] Zgurskaya, H. I. (2009) Multicomponent drug efflux complexes: architecture and mechanism of assembly, *Future Microbiol* 4, 919-932.

[17] Ziha-Zarifi, I., Llanes, C., Kohler, T., Pechere, J. C., and Plesiat, P. (1999) In vivo emergence of multidrug-resistant mutants of *Pseudomonas aeruginosa* overexpressing the active efflux system MexA-MexB-OprM, *Antimicrob Agents Chemother* 43, 287-291.

[18] Swick, M. C., Morgan-Linnell, S. K., Carlson, K. M., and Zechiedrich, L. (2011) Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in *Escherichia coli* clinical isolates as a function of fluoroquinolone and multidrug resistance, *Antimicrob Agents Chemother* 55, 921-924.

[19] Padilla, E., Llobet, E., Doménech-Sánchez, A., Martínez-Martínez, L., Bengoechea, J. A., and Albertí, S. (2010) *Klebsiella pneumoniae* AcrAB Efflux Pump Contributes to Antimicrobial Resistance and Virulence, *Antimicrobial Agents and Chemotherapy* 54, 177-183.

[20] Chiu, C.-H., Lee, H.-Y., Tseng, L.-Y., Chen, C.-L., Chia, J.-H., Su, L.-H., and Liu, S.-Y. (2010) Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in *Acinetobacter baumannii* clinical isolates in Taiwan, *International Journal of Antimicrobial Agents* 35, 382-386.

[21] Caroff, M., and Karibian, D. (2003) Structure of bacterial lipopolysaccharides, *Carbohydrate Research* 338, 2431-2447.

[22] Kocincova, D., and Lam, J. S. (2011) Structural diversity of the core oligosaccharide domain of *Pseudomonas aeruginosa* lipopolysaccharide, *Biochemistry Moscow* 76, 755-760.

[23] Pier, G. B. (2007) *Pseudomonas aeruginosa* lipopolysaccharide: A major virulence factor, initiator of inflammation and target for effective immunity, *International Journal of Medical Microbiology* 297, 277-295.

[24] Ernst, R. K., Moskowitz, S. M., Emerson, J. C., Kraig, G. M., Adams, K. N., Harvey, M. D., Ramsey, B., Speert, D. P., Burns, J. L., and Miller, S. I. (2007) Unique Lipid A Modifications in *Pseudomonas aeruginosa* Isolated from the Airways of Patients with Cystic Fibrosis, *Journal of Infectious Diseases* 196, 1088-1092.

[25] Ernst, R. K., Hajjar, A. M., Tsai, J. H., Moskowitz, S. M., Wilson, C. B., and Miller, S. I. (2003) *Pseudomonas aeruginosa* lipid A diversity and its recognition by Toll-like receptor 4, *Journal of Endotoxin Research* 9, 395-400.

[26] De Soyza, A., Silipo, A., Lanzetta, R., Govan, J. R., and Molinaro, A. (2008) Review: Chemical and biological features of *Burkholderia cepacia* complex lipopolysaccharides, *Innate Immunity* 14, 127-144.

[27] Beceiro, A., Llobet, E., Aranda, J., Bengoechea, J. A., Doumith, M., Hornsey, M., Dhanji, H., Chart, H., Bou, G., Livermore, D. M., and Woodford, N. (2011) Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of *Acinetobacter baumannii* Mediated by the pmrAB Two-Component Regulatory System, *Antimicrobial Agents and Chemotherapy* 55, 3370-3379.

[28] Plésiat, P., and Nikaido, H. (1992) Outer membranes of Gram-negative bacteria are permeable to steroid probes, *Molecular Microbiology* 6, 1323-1333.

[29] Plesiat, P., Aires, J. R., Godard, C., and Köhler, T. (1997) Use of steroids to monitor alterations in the outer membrane of *Pseudomonas aeruginosa*, *Journal of Bacteriology* 179, 7004-7010.

[30] Caroff, M., and Karibian, D. (2003) Structure of bacterial lipopolysaccharides, *Carbohydr Res* 338, 2431-2447.

[31] Knirel, Y. A., Bystrova, O. V., Kocharova, N. A., Zahringer, U., and Pier, G. B. (2006) Conserved and variable structural features in the lipopolysaccharide of *Pseudomonas aeruginosa*, *J Endotoxin Res* 12, 324-336.

[32] Bystrova, O. V., Lindner, B., Moll, H., Kocharova, N. A., Knirel, Y. A., Zahringer, U., and Pier, G. B. (2004) Full structure of the lipopolysaccharide of *Pseudomonas aeruginosa* immunotype 5, *Biochemistry (Mosc)* 69, 170-175.

[33] Isshiki, Y., Zähringer, U., and Kawahara, K. (2003) Structure of the core-oligosaccharide with a characteristic d-glycero- α -d-talo-oct-2-ulosylonate-(2 \rightarrow 4)-3-deoxy-d-manno-oct-2-ulosonate [α -Ko-(2 \rightarrow 4)-Kdo] disaccharide in the lipopolysaccharide from *Burkholderia cepacia*, *Carbohydrate Research* 338, 2659-2666.

[34] Vinogradov, E. V., Müller-Loennies, S., Petersen, B. O., Meshkov, S., Thomas-Oates, J. E., Holst, O., and Brade, H. (1997) Structural Investigation of the Lipopolysaccharide from *Acinetobacter Haemolyticus* Strain NCTC 10305 (ATCC 17906, DNA Group 4), *European Journal of Biochemistry* 247, 82-90.

[35] Vinion-Dubiel, A. D., and Goldberg, J. B. (2003) Review: Lipopolysaccharide of *Burkholderia cepacia* complex, *Journal of Endotoxin Research* 9, 201-213.

[36] Murata, T., Tseng, W., Guina, T., Miller, S. I., and Nikaido, H. (2007) PhoPQ-Mediated Regulation Produces a More Robust Permeability Barrier in the Outer Membrane of *Salmonella enterica* Serovar *Typhimurium*, *Journal of Bacteriology* 189, 7213-7222.

[37] Raetz, C. R. H., Reynolds, C. M., Trent, M. S., and Bishop, R. E. (2007) Lipid A Modification Systems in Gram-Negative Bacteria, *Annual Review of Biochemistry* 76, 295-329.

[38] Guo, L., Lim, K. B., Gunn, J. S., Bainbridge, B., Darveau, R. P., Hackett, M., and Miller, S. I. (1997) Regulation of Lipid A Modifications by *Salmonella typhimurium* Virulence Genes *phoP-phoQ*, *Science* 276, 250-253.

[39] Olaitan, A. O., Morand, S., and Rolain, J.-M. (2014) Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria, *Frontiers in Microbiology* 5.

[40] Jo, S., Wu, E., Stuhlsatz, D., Klauda, J., MacKerell, A., Jr., Widmalm, G., and Im, W. (2015) Lipopolysaccharide Membrane Building and Simulation, In *Glycoinformatics* (Lütteke, T., and Frank, M., Eds.), pp 391-406, Springer New York.

[41] Khalid, S., Berglund, N. A., Holdbrook, D. A., Leung, Y. M., and Parkin, J. (2015) The membranes of Gram-negative bacteria: progress in molecular modelling and simulation, *Biochem Soc Trans* 43, 162-167.

[42] Nikaido, H., and Pages, J. M. (2012) Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria, *FEMS Microbiol Rev* 36, 340-363.

[43] Pages, J. M., James, C. E., and Winterhalter, M. (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria, *Nat Rev Microbiol* 6, 893-903.

[44] Pletzer, D., Braun, Y., Dubiley, S., Lafon, C., Köhler, T., Page, M. G. P., Mourez, M., Severinov, K., and Weingart, H. (2015) The *Pseudomonas aeruginosa* PA14 ABC Transporter NppA1A2BCD Is Required for Uptake of Peptidyl Nucleoside Antibiotics, *Journal of Bacteriology* 197, 2217-2228.

[45] Krishnamoorthy, G., Tikhonova, E. B., Dhamdhare, G., and Zgurskaya, H. I. (2013) On the role of TolC in multidrug efflux: the function and assembly of AcrAB-TolC tolerate significant depletion of intracellular TolC protein, *Mol Microbiol* 87, 982-997.

[46] Weeks, J. W., Celaya-Kolb, T., Pecora, S., and Misra, R. (2010) AcrA suppressor alterations reverse the drug hypersensitivity phenotype of a TolC mutant by inducing TolC aperture opening, *Mol Microbiol* 75, 1468-1483.

[47] Tamber, S., and Hancock, R. E. (2004) The outer membranes of Pseudomonads, In *Pseudomonas* (Ramos, J.-L., Ed.), pp 575-601, Kluwer Academic/Plenum Publishers, New York.

[48] Sugawara, E., and Nikaido, H. (2012) OmpA Is the Principal Nonspecific Slow Porin of *Acinetobacter baumannii*, *Journal of Bacteriology* 194, 4089-4096.

[49] Vila, J., Martí, S., and Sánchez-Céspedes, J. (2007) Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*, *Journal of Antimicrobial Chemotherapy* 59, 1210-1215.

[50] Sugawara, E., Nagano, K., and Nikaido, H. (2012) Alternative folding pathways of the major porin OprF of *Pseudomonas aeruginosa*, *FEBS J* 279, 910-918.

[51] Sugawara, E., Nestorovich, E. M., Bezrukova, S. M., and Nikaido, H. (2006) *Pseudomonas aeruginosa* Porin OprF Exists in Two Different Conformations, *Journal of Biological Chemistry* 281, 16220-16229.

[52] Sugawara, E., and Nikaido, H. (2012) OmpA is the principal nonspecific slow porin of *Acinetobacter baumannii*, *J Bacteriol* 194, 4089-4096.

[53] Zahn, M., D'Agostino, T., Eren, E., Baslé, A., Ceccarelli, M., and van den Berg, B. (2015) Small-Molecule Transport by CarO, an Abundant Eight-Stranded β -Barrel Outer Membrane Protein from *Acinetobacter baumannii*, *Journal of Molecular Biology* 427, 2329-2339.

[54] Mussi, M. A., Limansky, A. S., and Viale, A. M. (2005) Acquisition of Resistance to Carbapenems in Multidrug-Resistant Clinical Strains of *Acinetobacter baumannii*: Natural Insertional Inactivation of a Gene Encoding a Member of a Novel Family of β -Barrel Outer Membrane Proteins, *Antimicrobial Agents and Chemotherapy* 49, 1432-1440.

[55] Borneleit, P., and Kleber, H.-P. (1991) The outer membrane of *Acinetobacter*: structure-function relationships, In *The Biology of Acinetobacter* (Towner, K. J., Bergogne-Berezin, E., and Fewson, C. A., Eds.), pp 259-272, Plenum Press, New York and London.

[56] SIRITAPETAWEE, J., PRINZ, H., KRITTANAI, C., and SUGINTA, W. (2004) *Expression and refolding of Omp38 from Burkholderia pseudomallei and Burkholderia thailandensis, and its function as a diffusion porin*, Vol. 384.

[57] Suginta, W., Mahendran, K. R., Chumjan, W., Hajjar, E., Schulte, A., Winterhalter, M., and Weingart, H. (2011) Molecular analysis of antimicrobial agent translocation through the membrane porin BpsOmp38 from an ultraresistant Burkholderia pseudomallei strain, *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1808, 1552-1559.

[58] SIRITAPETAWEE, J., PRINZ, H., SAMOSORNSUK, W., ASHLEY, R. H., and SUGINTA, W. (2004) Functional reconstitution, gene isolation and topology modelling of porins from Burkholderia pseudomallei and Burkholderia thailandensis, *Biochemical Journal* 377, 579-587.

[59] Tikhonova, E. B., Dastidar, V., Rybenkov, V. V., and Zgurskaya, H. I. (2009) Kinetic control of TolC recruitment by multidrug efflux complexes, *Proc Natl Acad Sci U S A* 106, 16416-16421.

[60] Tikhonova, E. B., Yamada, Y., and Zgurskaya, H. I. (2011) Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC, *Chemistry & biology* 18, 454-463.

[61] Tikhonova, E. B., and Zgurskaya, H. I. (2004) AcrA, AcrB, and TolC of Escherichia coli Form a Stable Intermembrane Multidrug Efflux Complex, *J Biol Chem* 279, 32116-32124.

[62] Nikaido, H., and Zgurskaya, H. I. (1999) Antibiotic efflux mechanisms, *Curr Opin Infect Dis* 12, 529-536.

[63] Phillips, J. L., and Gnanakaran, S. (2015) A data-driven approach to modeling the tripartite structure of multidrug resistance efflux pumps, *Proteins: Structure, Function, and Bioinformatics* 83, 46-65.

[64] Zgurskaya, H. I., and Nikaido, H. (1999) Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of Escherichia coli, *Proc Natl Acad Sci USA* 96, 7190-7195.

[65] Yu, E. W., McDermott, G., Zgurskaya, H. I., Nikaido, H., and Koshland, D. E., Jr. (2003) Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump, *Science* 300, 976-980.

[66] Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T., and Yamaguchi, A. (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism, *Nature* 443, 173-179.

[67] Vargiu, A. V., and Nikaido, H. (2012) Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations, *Proc Natl Acad Sci U S A* 109, 20637-20642.

[68] Nakashima, R., Sakurai, K., Yamasaki, S., Nishino, K., and Yamaguchi, A. (2011) Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket, *Nature* 480, 565-569.

[69] Nagano, K., and Nikaido, H. (2009) Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli, *Proc Natl Acad Sci U S A* 106, 5854-5858.

[70] Poole, K., and Srikumar, R. (2001) Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance, *Current topics in medicinal chemistry* 1, 59-71.

[71] Pumbwe, L., and Piddock, L. J. (2000) Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa, *Antimicrob Agents Chemother* 44, 2861-2864.

[72] Poole, K. (2004) Efflux-mediated multiresistance in Gram-negative bacteria, *Clin Microbiol Infect* 10, 12-26.

[73] Aendekerk, S., Diggle, S. P., Song, Z., Hoiby, N., Cornelis, P., Williams, P., and Camara, M. (2005) The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication, *Microbiology* 151, 1113-1125.

[74] Hirakata, Y., Srikumar, R., Poole, K., Gotoh, N., Suematsu, T., Kohno, S., Kamihira, S., Hancock, R. E., and Speert, D. P. (2002) Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa, *J Exp Med* 196, 109-118.

[75] Podneicky, N. L., Rhodes, K. A., and Schweizer, H. P. (2015) Efflux Pump-mediated Drug Resistance in *Burkholderia*, *Frontiers in Microbiology* 6.

[76] Buroni, S., Matthijs, N., Spadaro, F., Van Acker, H., Scoffone, V. C., Pasca, M. R., Riccardi, G., and Coenye, T. (2014) Differential Roles of RND Efflux Pumps in Antimicrobial Drug Resistance of Sessile and Planktonic *Burkholderia cenocepacia* Cells, *Antimicrobial Agents and Chemotherapy* 58, 7424-7429.

[77] Coyne, S., Courvalin, P., and Périchon, B. (2011) Efflux-Mediated Antibiotic Resistance in *Acinetobacter* spp, *Antimicrobial Agents and Chemotherapy* 55, 947-953.

[78] Yoon, E.-J., Nait Chabane, Y., Goussard, S., Snesrud, E., Courvalin, P., Dé, E., and Grillot-Courvalin, C. (2015) Contribution of Resistance-Nodulation-Cell Division Efflux Systems to Antibiotic Resistance and Biofilm Formation in *Acinetobacter baumannii*, *mBio* 6.

[79] Sulavik, M. C., Houseweart, C., Cramer, C., Jiwani, N., Murgolo, N., Greene, J., DiDomenico, B., Shaw, K. J., Miller, G. H., Hare, R., and Shimer, G. (2001) Antibiotic Susceptibility Profiles of *Escherichia coli* Strains Lacking Multidrug Efflux Pump Genes, *Antimicrob Agents Chemother* 45, 1126-1136.

[80] Tal, N., and Schuldiner, S. (2009) A coordinated network of transporters with overlapping specificities provides a robust survival strategy, *Proceedings of the National Academy of Sciences* 106, 9051-9056.

[81] Lee, A., Mao, W., Warren, M. S., Mistry, A., Hoshino, K., Okumura, R., Ishida, H., and Lomovskaya, O. (2000) Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance, *J Bacteriol* 182, 3142-3150.

[82] Zgurskaya, H. I., and Nikaido, H. (2002) Mechanistic parallels in bacterial and human multidrug efflux transporters, *Curr Protein Pept Sci* 3, 531-540.

[83] Fluman, N., and Bibi, E. (2009) Bacterial multidrug transport through the lens of the major facilitator superfamily, *Biochim Biophys Acta* 1794, 738-747.

[84] Schuldiner, S. (2009) EmrE, a model for studying evolution and mechanism of ion-coupled transporters, *Biochim Biophys Acta* 1794, 748-762.

[85] Kuroda, T., and Tsuchiya, T. (2009) Multidrug efflux transporters in the MATE family, *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* 1794, 763-768.

[86] Walsh, C. T., and Wencewicz, T. A. (2014) Prospects for new antibiotics: a molecule-centered perspective, *J Antibiot (Tokyo)* 67, 7-22.

[87] Pucci, M. J., and Bush, K. (2013) Investigational Antimicrobial Agents of 2013, *Clinical Microbiology Reviews* 26, 792-821.

[88] Schalk, I. J., Mislin, G. L. A., and Brillet, K. (2012) Chapter Two - Structure, Function and Binding Selectivity and Stereoselectivity of Siderophore-Iron Outer Membrane Transporters, In *Current Topics in Membranes* (José, M. A., and Svetlana, L., Eds.), pp 37-66, Academic Press.

[89] Braun, V., and Hantke, K. (2011) Recent insights into iron import by bacteria, *Current Opinion in Chemical Biology* 15, 328-334.

[90] Cunrath, O., Geoffroy, V. A., and Schalk, I. J. (2015) Metallome of *Pseudomonas aeruginosa*: a role for siderophores, *Environmental microbiology*, n/a-n/a.

[91] Page, M. G. P. (2013) Siderophore conjugates, *Annals of the New York Academy of Sciences* 1277, 115-126.

[92] Page, M. G. P., Dantier, C., and Desarbre, E. (2010) In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli, *Antimicrobial Agents and Chemotherapy* 54, 2291-2302.

[93] Chen, R. H., Buko, A. M., Whittern, D. N., and McAlpine, J. B. (1989) Pacidamycins, a novel series of antibiotics with anti-*Pseudomonas aeruginosa* activity. II. Isolation and structural elucidation, *J Antibiot (Tokyo)* 42, 512-520.

[94] Fernandes, P. B., Swanson, R. N., Hardy, D. J., Hanson, C. W., Coen, L., Rasmussen, R. R., and Chen, R. H. (1989) Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile, *J Antibiot (Tokyo)* 42, 521-526.

[95] Karwowski, J. P., Jackson, M., Theriault, R. J., Chen, R. H., Barlow, G. J., and Maus, M. L. (1989) Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. I. Taxonomy of the producing organism and fermentation, *J Antibiot (Tokyo)* 42, 506-511.

[96] Mistry, A., Warren, M. S., Cusick, J. K., Karkhoff-Schweizer, R. R., Lomovskaya, O., and Schweizer, H. P. (2013) High-Level Pacidamycin Resistance in Pseudomonas aeruginosa Is Mediated by an Opp Oligopeptide Permease Encoded by the opp-fabI Operon, *Antimicrobial Agents and Chemotherapy* 57, 5565-5571.

[97] O'Shea, R., and Moser, H. E. (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery, *J Med Chem* 51, 2871-2878.

[98] Burns, A. R., Wallace, I. M., Wildenhain, J., Tyers, M., Giaever, G., Bader, G. D., Nislow, C., Cutler, S. R., and Roy, P. J. (2010) A predictive model for drug bioaccumulation and bioactivity in *Caenorhabditis elegans*, *Nat Chem Biol* 6, 549-557.

[99] Davis, T. D., Gerry, C. J., and Tan, D. S. (2014) General Platform for Systematic Quantitative Evaluation of Small-Molecule Permeability in Bacteria, *ACS Chemical Biology* 9, 2535-2544.

[100] Zhou, Y., Joubran, C., Miller-Vedam, L., Isabella, V., Nayar, A., Tentarelli, S., and Miller, A. (2015) Thinking Outside the "Bug": A Unique Assay To Measure Intracellular Drug Penetration in Gram-Negative Bacteria, *Analytical Chemistry* 87, 3579-3584.

[101] Manchester, J. I., Buurman, E. T., Bisacchi, G. S., and McLaughlin, R. E. (2012) Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery, *J Med Chem* 55, 2532-2537.

[102] Parkin, J., Chavent, M., and Khalid, S. (2015) Molecular Simulations of Gram-Negative Bacterial Membranes: A Vignette of Some Recent Successes, *Biophysical Journal* 109, 461-468.

[103] Berglund, N. A., Piggot, T. J., Jefferies, D., Sessions, R. B., Bond, P. J., and Khalid, S. (2015) Interaction of the antimicrobial peptide polymyxin B1 with both membranes of *E. coli*: a molecular dynamics study, *PLoS Comput Biol* 11, e1004180.

[104] Bohnert, J. A., and Kern, W. V. (2005) Selected arylpiperazines are capable of reversing multidrug resistance in *Escherichia coli* overexpressing RND efflux pumps, *Antimicrob Agents Chemother* 49, 849-852.

[105] Renau, T. E., Leger, R., Filonova, L., Flamme, E. M., Wang, M., Yen, R., Madsen, D., Griffith, D., Chamberland, S., Dudley, M. N., Lee, V. J., Lomovskaya, O., Watkins, W. J., Ohta, T., Nakayama, K., and Ishida, Y. (2003) Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in *Pseudomonas aeruginosa*, *Bioorg Med Chem Lett* 13, 2755-2758.

[106] Watkins, W. J., Landaverry, Y., Leger, R., Litman, R., Renau, T. E., Williams, N., Yen, R., Zhang, J. Z., Chamberland, S., Madsen, D., Griffith, D., Tembe, V., Huie, K., and Dudley, M. N. (2003) The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors, *Bioorg Med Chem Lett* 13, 4241-4244.

[107] Opperman, T. J., and Nguyen, S. T. (2015) Recent advances toward a molecular mechanism of efflux pump inhibition, *Frontiers in Microbiology* 6.

[108] Lomovskaya, O., Zgurskaya, H. I., and Bostian, K. A. (2008) Bacterial Multidrug Transporters: Molecular and Clinical Aspects., In *Transporters as Drug Carriers* (Ecker, G. F., and Chiba, P., Eds.), p in press, Wiley and Sons.

[109] Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., Leger, R., Hecker, S., Watkins, W., Hoshino, K., Ishida, H., and Lee, V.

J. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy, *Antimicrob Agents Chemother* 45, 105-116.

[110] Watkins, W. J., Chong, L., Cho, A., Hilgenkamp, R., Ludwikow, M., Garizi, N., Iqbal, N., Barnard, J., Singh, R., Madsen, D., Lolans, K., Lomovskaya, O., Oza, U., Kumaraswamy, P., Blecken, A., Bai, S., Loury, D. J., Griffith, D. C., and Dudley, M. N. (2007) Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization, *Bioorg Med Chem Lett* 17, 2802-2806.

[111] Thorarensen, A., Presley-Bodnar, A. L., Marotti, K. R., Boyle, T. P., Heckaman, C. L., Bohanon, M. J., Tomich, P. K., Zurenko, G. E., Sweeney, M. T., and Yagi, B. H. (2001) 3-Arylpiperidines as potentiators of existing antibacterial agents, *Bioorganic & Medicinal Chemistry Letters* 11, 1903-1906.

[112] Opperman, T. J., Kwasny, S. M., Kim, H.-S., Nguyen, S. T., Houseweart, C., D'Souza, S., Walker, G. C., Peet, N. P., Nikaido, H., and Bowlin, T. L. (2014) Characterization of a Novel Pyranopyridine Inhibitor of the AcrAB Efflux Pump of *Escherichia coli*, *Antimicrobial Agents and Chemotherapy* 58, 722-733.

[113] Chevalier, J., Mahamoud, A., Baitiche, M., Adam, E., Viveiros, M., Smarandache, A., Militaru, A., Pascu, M. L., Amaral, L., and Pagès, J.-M. (2010) Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in *Enterobacter aerogenes*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* resistant strains, *International journal of antimicrobial agents* 36, 164-168.

[114] Lomovskaya, O., and al., e. (1999) Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in *Pseudomonas aeruginosa*., *Antimicrob. Agents Chemother.* 43, 1340-1346.

Table 1. Major porins and efflux pumps of Gram-negative bacteria.

Species	Relative OM Permeability	Major Porins	Major Efflux Pumps
<i>E. coli</i>	100%	OmpF/OmpC	AcrAB-TolC
<i>P. aeruginosa</i>	1-8%	OprF	MexAB-OprM, MexXY-OprM
<i>B. cepacia</i>	11%	OpcP1/OpcP2	AmrAB-OprA, BpeAB-OprB, BpeEF-OprC
<i>A. baumannii</i>	1-5%	OmpA-AB	AdeABC and AdeIJK